MedTrace Logo

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-19

No results posted yet for this study

Summary

This is an open-label, single arm, non-randomized, multicenter phase II study for the identification of predictive biomarkers of sacituzumab govitecan benefit and the understanding of key resistance mechanisms in HR+/HER2- advanced/metastatic breast cancer patients

Conditions

  • Breast Cancer Stage IV

Interventions

DRUG

Sacituzumab Govitecan

Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle

Sponsors & Collaborators

  • SOLTI Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Eva Ciruelos, MD · Hospital 12 de Octubre, Madrid/SOLTI

  • Mafalda Oliveira, MD · Hospital Vall d'Hebrón/SOLTI

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-02-20
Completion
2027-02-20

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236269 on ClinicalTrials.gov